Member Info for Laura2022

Have not gone,far from it, simply can't be guaranteed to be hitting bottomnline before the June end reailts

This will be due to red tape etc one assumes from client side

these two projects will be signed in FY24, the majority of the revenue is now expected be recognised in the Company's next financial year ending 30 June 2025 ("FY25"), and accordingly the Board's expectations for FY25 revenues have been correspondingly increased. 

The Board notes that the Company has, to date, secured £225k of revenue in respect of FY25 which is expected to increase to over £0.5 million on the signing of the two aforementioned contracts.

Not sure why people do such a U turn in views

10p for £5mln confirmed

Thanks uncanny

You've answered my question

Is this separate to the acquisition of the Malaysian company d you know please ?

It mentions they acquired a company in May 2024

The role /expansion was explained in presentation November I think

Ie wanted someone full time and IN HOUSE

From March 2024

A significant number of new client contracts are now originating from both scientific conferences (such as EORTC-NCI-AACR & AACR Annual Meeting) as well as more business focused meetings (such as BioEurope

Morning Carliol

They also completed 2 very large conference in April too ,would expect more business to come form there too

Thanks Trench

The FDA Centre of excellence looks very exciting

Https://www.fda.gov/drugs/drug-safety-and-availability/cder-establishes-new-quantitative-medicine-center-excellence

FDA’s Center for Drug Evaluation and Research (CDER) announces new Quantitative Medicine Centre of Excellence

At Physiomics we have long understood the importance and application of quantitative medicine in the development of new therapeutic drugs. Over the years we have used this expertise to strengthen our clients’ evidence and understanding of their drugs’ behaviour, in both safety and efficacy, to de-risk their development journey.

By establishing the QM Centre of Excellence, an institute dedicated to application and development of quantitative modelling and simulation approaches, the FDA are recognising the need for this expertise in streamlining development of new therapeutic drugs.

The aim of the QM Center of Excellence is “to facilitate and coordinate the continuous evolution and consistent application of QM across CDER”.

Furthermore, this is another signal that the regulators are increasingly encouraging and expecting model-based evidence in regulatory applications and assessments. To learn more about Physiomics’ expertise in quantitative pharmacology and how this can be applied to de-risk decisions and make the development of your therapeutic pipeline more efficient, please get in touch!

Afternoon Carliol

At the current £1 7mln market capitalisation PYC is a very good buy

Morning Ant

Yes,yesterday I put an order in and today I cannot buy at all

FY June 2024-25 looks good with £0.6mln already booked in before it even starts and also due to hear from

Biostatistics service line

 

The Company was excited to announce its intention to develop a separate consulting service line focused on the delivery of biostatistics projects. Several complementary options are being pursued simultaneously to build out this new capability and a further update will be provided to the market towards the end of the current financial year. We anticipate that, if successful, this new service line could make a material contribution to the Company's revenues and bottom line in the financial year ending 30 June 2025.

BioPartner UK is the independent, accredited trade organisation that supports UK international trade

We work with conference organisers, in-country agencies and overseas networks to provide the best business opportunities for our members and UK companies travelling with outward delegations. BioPartner also provides access to entry fee discounts for key Life Science conferences.

The BIO International Convention is the largest biotechnology event of the year, with >20,000 industry leaders attending from across the globe. Physiomics’ CEO, Peter Sargent, and Head of Business Development, Hayley Close will be attending the event to meet with decision makers from leading pharma & biotech companies. Physiomics will be looking to identify opportunities where the company’s expertise in quantitative pharmacology and PKPD modelling can be applied to derisk R&D of therapeutics drugs, across indications for the companies attending.

Welcome to the @BioPartner family, @Physiomics.

We are looking forward to a wonderful #partnership with exciting #opportunities ahead. 🤝

Hard buying again , I managed £700

Great news

Cancer experts have claimed that the UK is entering a 'cancer renaissance' with personalised jabs to combat some of the deadliest tumours expected by 2030.

The vaccines are designed to target specific genetic mutations found in cancer cells. This means that, should the cancer return, the immune system will spot it immediately and destroy the cells before they have time to spread.

Kate Bingham tells NHS to launch experimental cancer vaccine trials with pioneering technology that trains the immune system how to hunt malignant cells

https://www.dailymail.co.uk/health/article-13383755/Former-Covid-jab-tsar-tells-NHS-launch-experimental-cancer-vaccine-trials-pioneering-technology-trains-immune-hunt-malignant-cells.html

“Dr Lennard Lee, a cancer vaccine expert at the University of Oxford, said there are now 12 drug manufacturers testing cancer jabs in the UK. He added: 'We are already gaining the reputation as the best country in the world to develop cancer vaccines.'

This was a post on linked in from a month ago

Robert Watson

•

Clinical Lecturer, University of Oxford | Oncologist | Physician Scientist | Tumour Immunologist

Clinical Lecturer, University of Oxford | Oncologist | Physician Scientist | Tumour Immunologist

1mo •

From a month ago F

Fascinating to attend an investigator meeting for Scancell Ltd's SCOPE study - the second meeting for a

hashtag

#cancervaccine clinical trial in melanoma that I've been to in the space of a few weeks. Great to hear about the immunology underpinning the therapy and enjoyable to interact with other trial teams around the UK. It is really fantastic to be able to offer these cutting-edge clinical trials to our patients at Oxford University Hospitals NHS Foundation Trust and see such rapid ongoing progress in the cancer vaccine space